On 10 June, Philochem (a Philogen subsidiary) granted RayzeBio (a BMS subsidiary) exclusive global rights to develop, manufacture and commercialise OncoACP3, a clinical-stage prostate cancer theranostic. The USD 350 million-upfront deal includes up to USD 1 billion in milestones and tiered royalties.

OncoACP3 targets acidic phosphatase 3 (ACP3) with high specificity, enabling diagnostic (68Ga/18F-OncoACP3) and therapeutic (177Lu/225Ac-OncoACP3) radiopharmaceutical development. The 68Ga-OncoACP3 Phase I trial (NCT06840535) showed selective tumour uptake with minimal healthy tissue absorption.

RayzeBio President Ben Hickey stated the deal aligns with their best-in-class radiopharmaceutical strategy, leveraging OncoACP3's safety profile and actinium-based RPT expertise. IND preparation for 225Ac-OncoACP3 is underway.